BERKELEY, Calif. – April 1, 2026 – Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that

Industry veteran brings global regulatory expertise to support development of innovative optogenetic gene therapies

Seasoned biopharma industry leader brings more than 30 years of experience to support company’s growth trajectory